Increased protective efficacy of recombinant BCG strains expressing virulence-neutral proteins of the ESX-1 secretion system

Vaccine

Volumn 33, Issue 23, 2015, Pages 2710-2718

  Bottai, Daria ^a,b   Frigui, Wafa ^a   Clark, Simon ^c   Rayner, Emma ^c   Zelmer, Andrea ^d   Andreu, Nuria ^d   de Jonge, Marien I ^e   Bancroft, Gregory J ^d   Williams, Ann ^c   Brodin, Priscille ^f   Brosch, Roland ^a  

^a INSTITUT PASTEUR   (France)

^b UNIVERSITY OF PISA   (Italy)

^c PUBLIC HEALTH ENGLAND   (United Kingdom)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^f UNIV LILLE   (France)

Author keywords

ESAT 6; ESX 1 secretion system; Recombinant BCG; Tuberculosis; Vaccine

Indexed keywords

BCG VACCINE; EARLY SECRETORY ANTIGENIC TARGET 6; LEUCINE; BACTERIAL ANTIGEN; BACTERIAL PROTEIN; ESAT-6 PROTEIN, MYCOBACTERIUM TUBERCULOSIS; RECOMBINANT VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL LOAD; BACTERIAL SECRETION SYSTEM; BACTERIAL VIRULENCE; BACTERIUM CULTURE; BCG VACCINATION; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; ESX 1 SECRETION SYSTEM; FEMALE; HARTLEY GUINEA PIG; LOW DRUG DOSE; LUNG; MOUSE; MYCOBACTERIUM BOVIS BCG; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SINGLE DRUG DOSE; SPLEEN; TUBERCULOSIS; ANIMAL; BACTERIAL COUNT; BIOSYNTHESIS; C57BL MOUSE; GENETICS; GUINEA PIG; IMMUNOLOGY; MALE; MICROBIOLOGY; SCID MOUSE; SURVIVAL; TREATMENT OUTCOME; VIRULENCE;

ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; BCG VACCINE; COLONY COUNT, MICROBIAL; FEMALE; GUINEA PIGS; LUNG; MALE; MICE, INBRED C57BL; MICE, SCID; SPLEEN; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUBERCULOSIS; VACCINES, SYNTHETIC; VIRULENCE;

EID: 84929042801     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.03.083     Document Type: Article

References (42)

1. Andersen P., Kaufmann S.H. Novel vaccination strategies against tuberculosis. Cold Spring Harb Perspect Med 2014, 4(6.):a018523.
2. Delogu G., Manganelli R., Brennan M.J. Critical research concepts in tuberculosis vaccine development. Clin Microbiol Infect 2014, 20:59-65.
3. Pym A.S., Brodin P., Majlessi L., Brosch R., Demangel C., Williams A., et al. Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. Nat Med 2003, 9:533-539.
4. Mahairas G.G., Sabo P.J., Hickey M.J., Singh D.C., Stover C.K. Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis. J Bacteriol 1996, 178:1274-1282.
5. Behr M.A., Wilson M.A., Gill W.P., Salamon H., Schoolnik G.K., Rane S., et al. Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science 1999, 284:1520-1523.
6. Bange F.C., Collins F.M., Jacobs W.R. Survival of mice infected with Mycobacterium smegmatis containing large DNA fragments from Mycobacterium tuberculosis. Tuberc Lung Dis 1999, 79:171-180.
7. Bitter W., Houben E.N., Bottai D., Brodin P., Brown E.J., Cox J.S., et al. Systematic genetic nomenclature for type VII secretion systems. PLoS Pathog 2009, 5:e1000507.
8. Bottai D., Stinear T., Supply P., Brosch R. Mycobacterial pathogenomics and evolution. Microbiol Spectr 2014, 2. MGM2-0025-2013.
9. Simeone R., Sayes F., Song O., Groschel M.I., Brodin P., Brosch R., et al. Cytosolic access of Mycobacterium tuberculosis: critical impact of phagosomal acidification control and demonstration of occurrence in vivo. PLoS Pathog 2015, 11:e1004650.
10. Pym A.S., Brodin P., Brosch R., Huerre M., Cole S.T. Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti. Mol Microbiol 2002, 46:709-717.
11. Brodin P., Majlessi L., Brosch R., Smith D., Bancroft G., Clark S., et al. Enhanced protection against tuberculosis by vaccination with recombinant Mycobacterium microti vaccine that induces T cell immunity against region of difference 1 antigens. J Infect Dis 2004, 190:115-122.
12. Majlessi L., Prados-Rosales R., Casadevall A., Brosch R. Release of mycobacterial antigens. Immunol Rev 2015, 264:25-45.
13. Brodin P., de Jonge M.I., Majlessi L., Leclerc C., Nilges M., Cole S.T., et al. Functional analysis of early secreted antigenic target-6, the dominant T-cell antigen of Mycobacterium tuberculosis, reveals key residues involved in secretion, complex formation, virulence, and immunogenicity. J Biol Chem 2005, 280:33953-33959.
14. Cole S.T., Brosch R., Parkhill J., Garnier T., Churcher C., Harris D., et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998, 393:537-544.
15. Caminero J.A., Pena M.J., Campos-Herrero M.I., Rodriguez J.C., Garcia I., Cabrera P., et al. Epidemiological evidence of the spread of a Mycobacterium tuberculosis strain of the Beijing genotype on Gran Canaria Island. Am J Respir Crit Care Med 2001, 164:1165-1170.
16. Majlessi L., Brodin P., Brosch R., Rojas M.J., Khun H., Huerre M., et al. Influence of ESAT-6 secretion system 1 (RD1) of Mycobacterium tuberculosis on the interaction between mycobacteria and the host immune system. J Immunol 2005, 174:3570-3579.
17. Sander P., Clark S., Petrera A., Vilaplana C., Meuli M., Selchow P., et al. Deletion of zmp1 improves Mycobacterium bovis BCG-mediated protection in a guinea pig model of tuberculosis. Vaccine 2015, 33:1353-1359.
18. Demangel C., Brodin P., Cockle P.J., Brosch R., Majlessi L., Leclerc C., et al. Cell envelope protein PPE68 contributes to Mycobacterium tuberculosis RD1 immunogenicity independently of a 10-kilodalton culture filtrate protein and ESAT-6. Infect Immun 2004, 72:2170-2176.
19. Bottai D., Majlessi L., Simeone R., Frigui W., Laurent C., Lenormand P., et al. ESAT-6 secretion-independent impact of ESX-1 genes espF and espG1 on virulence of Mycobacterium tuberculosis. J Infect Dis 2011, 203:1155-1164.
20. Williams A., Davies A., Marsh P.D., Chambers M.A., Hewinson R.G. Comparison of the protective efficacy of bacille calmette-Guerin vaccination against aerosol challenge with Mycobacterium tuberculosis and Mycobacterium bovis. Clin Infect Dis 2000, 30:S299-S301.
21. Chambers M.A., Williams A., Gavier-Widen D., Whelan A., Hall G., Marsh P.D., et al. Identification of a Mycobacterium bovis BCG auxotrophic mutant that protects guinea pigs against M. bovis and hematogenous spread of Mycobacterium tuberculosis without sensitization to tuberculin. Infect Immun 2000, 68:7094-7099.
22. Williams A., James B.W., Bacon J., Hatch K.A., Hatch G.J., Hall G.A., et al. An assay to compare the infectivity of Mycobacterium tuberculosis isolates based on aerosol infection of guinea pigs and assessment of bacteriology. Tuberculosis 2005, 85:177-184. (Edinb).
23. Brosch R., Gordon S.V., Garnier T., Eiglmeier K., Frigui W., Valenti P., et al. Genome plasticity of BCG and impact on vaccine efficacy. Proc Natl Acad Sci U S A 2007, 104:5596-5601.
24. Williams A., Hatch G.J., Clark S.O., Gooch K.E., Hatch K.A., Hall G.A., et al. Evaluation of vaccines in the EU TB vaccine cluster using a guinea pig aerosol infection model of tuberculosis. Tuberculosis 2005, 85:29-38. (Edinb).
25. Grode L., Seiler P., Baumann S., Hess J., Brinkmann V., Nasser Eddine A., et al. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guerin mutants that secrete listeriolysin. J Clin Invest 2005, 115:2472-2479.
26. Lopez B., Aguilar D., Orozco H., Burger M., Espitia C., Ritacco V., et al. A marked difference in pathogenesis and immune response induced by different Mycobacterium tuberculosis genotypes. Clin Exp Immunol 2003, 133:30-37.
27. Arbues A., Aguilo J.I., Gonzalo-Asensio J., Marinova D., Uranga S., Puentes E., et al. Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tuberculosis-based vaccine to enter clinical trials. Vaccine 2013, 31:4867-4873.
28. Orme I.M. Induction of nonspecific acquired resistance and delayed-type hypersensitivity, but not specific acquired resistance in mice inoculated with killed mycobacterial vaccines. Infect Immun 1988, 56:3310-3312.
29. Romain F.A., Pescher J.P., Marchal G. Isolation of a proline-rich mycobacterial protein eliciting delayed-type hypersensitivity reactions only in guinea pigs immunised with living mycobacteria. Proc Natl Acad Sci U S A 1993, 90:5322-5326.
30. Simeone R., Bobard A., Lippmann J., Bitter W., Majlessi L., Brosch R., et al. Phagosomal rupture by Mycobacterium tuberculosis results in toxicity and host cell death. PLoS Pathog 2012, 8:e1002507.
31. Houben D., Demangel C., van Ingen J., Perez J., Baldeon L., Abdallah A.M., et al. ESX-1-mediated translocation to the cytosol controls virulence of mycobacteria. Cell Microbiol 2012, 14:1287-1298.
32. Frigui W., Bottai D., Majlessi L., Monot M., Josselin E., Brodin P., et al. Control of M. tuberculosis ESAT-6 secretion and specific T cell recognition by PhoP. PLoS Pathog 2008, 4:e33.
33. Lee J.S., Krause R., Schreiber J., Mollenkopf H.J., Kowall J., Stein R., et al. Mutation in the transcriptional regulator PhoP contributes to avirulence of Mycobacterium tuberculosis H37Ra strain. Cell Host Microb 2008, 3:97-103.
34. Boritsch E.C., Supply P., Honore N., Seeman T., Stinear T.P., Brosch R. A glimpse into the past and predictions for the future: the molecular evolution of the tuberculosis agent. Mol Microbiol 2014, 93:835-852.
35. Gagneux S., Small P.M. Global phylogeography of Mycobacterium tuberculosis and implications for tuberculosis product development. Lancet Infect Dis 2007, 7:328-337.
36. Orme I.M., Basaraba R.J. The formation of the granuloma in tuberculosis infection. Semin Immunol 2014, 26:601-609.
37. Martin C., Williams A., Hernandez-Pando R., Cardona P.J., Gormley E., Bordat Y., et al. The live Mycobacterium tuberculosis phoP mutant strain is more attenuated than BCG and confers protective immunity against tuberculosis in mice and guinea pigs. Vaccine 2006, 24:3408-3419.
38. Sweeney K.A., Dao D.N., Goldberg M.F., Hsu T., Venkataswamy M.M., Henao-Tamayo M., et al. A recombinant Mycobacterium smegmatis induces potent bactericidal immunity against Mycobacterium tuberculosis. Nat Med 2011, 17:1261-1268.
39. Sayes F., Sun L., Di Luca M., Simeone R., Degaiffier N., Fiette L., et al. Strong immunogenicity and cross-reactivity of Mycobacterium tuberculosis ESX-5 Type VII secretion-encoded PE-PPE proteins predicts vaccine potential. Cell Host Microb 2012, 11:352-363.
40. Horwitz M.A., Harth G. A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis. Infect Immun 2003, 71:1672-1679.
41. Gengenbacher M., Vogelzang A., Schuerer S., Lazar D., Kaiser P., Kaufmann S.H. Dietary pyridoxine controls efficacy of vitamin B6-auxotrophic tuberculosis vaccine bacillus Calmette-Guerin DeltaureC::hly Deltapdx1 in mice. MBio 2014, 5:e01262-e1314.
42. Pallen M.J. The ESAT-6/WXG100 superfamily-and a new gram-positive secretion system. Trends Microbiol 2002, 10:209-212.